ARO DM1
Alternative Names: ARO-DM1Latest Information Update: 13 Mar 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Myotonin protein kinase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Myotonic dystrophy
Most Recent Events
- 08 Mar 2024 Pharmacodynamics data from a preclinical studies in Myotonic Dystrophy released by Arrowhead Pharmaceuticals
- 04 Mar 2024 Phase-I/II clinical trials in Myotonic dystrophy in Australia (IV) (NCT06138743)
- 04 Mar 2024 Phase-I/II clinical trials in Myotonic dystrophy in New Zealand (IV) (NCT06138743)